Voyageur Historical Balance Sheet

VM Stock

CAD 0.06 0.01 10.00%

Trend analysis of Voyageur Pharmaceuticals balance sheet accounts such as Total Assets of 2.6 M, Total Current Liabilities of 418.5 K, Total Stockholder Equity of 1.7 M or Net Debt of 45.8 K provides information on Voyageur Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Voyageur Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Voyageur Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Voyageur Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Voyageur Pharmaceuticals is a good buy for the upcoming year.

Voyageur Pharmaceuticals Inventory

12,465.02

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Voyageur Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Voyageur Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Voyageur Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Voyageur Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Voyageur Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Voyageur currently owns. An asset can also be divided into two categories, current and non-current.

Voyageur Pharmaceuticals Balance Sheet Chart

At this time, Voyageur Pharmaceuticals' Inventory is fairly stable compared to the past year. Common Stock is likely to climb to about 10.5 M in 2024, whereas Cash is likely to drop 1,783 in 2024.

Total Assets Total Current Liabilities Cash And Short Term Investments Net Receivables

Total Assets

Total assets refers to the total amount of Voyageur Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Voyageur Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Voyageur Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Voyageur Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Voyageur Pharmaceuticals balance sheet. This account contains Voyageur Pharmaceuticals investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Voyageur Pharmaceuticals fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Most accounts from Voyageur Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Voyageur Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Voyageur Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

At this time, Voyageur Pharmaceuticals' Inventory is fairly stable compared to the past year. Common Stock is likely to climb to about 10.5 M in 2024, whereas Cash is likely to drop 1,783 in 2024.

	2021	2022	2023	2024 (projected)
Total Current Liabilities	591.3K	673.9K	775.0K	418.5K
Total Assets	2.1M	2.2M	2.5M	2.6M

Total Current Liabilities Total Assets

Voyageur Pharmaceuticals balance sheet Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Debt	Cash	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Total Liab	Total Current Assets	Retained Earnings	Other Stockholder Equity	Other Current Liab	Net Tangible Assets	Property Plant And Equipment Net	Accounts Payable	Non Current Assets Total	Other Assets	Inventory	Other Current Assets	Common Stock	Property Plant Equipment	Other Liab	Non Current Liabilities Total	Short Long Term Debt Total	Current Deferred Revenue
Total Assets		0.76	0.93	0.1	-0.03	-0.03	0.48	0.95	0.7	0.15	-0.94	0.92	0.68	0.94	0.38	0.31	0.92	0.78	0.4	0.51	0.94	0.91	-0.87	-0.88	-0.04	0.89
Total Current Liabilities	0.76		0.5	0.45	-0.28	-0.28	0.67	0.72	0.97	-0.08	-0.7	0.55	0.48	0.59	0.57	0.66	0.84	0.92	0.19	0.59	0.63	0.89	-0.82	-0.76	0.47	0.85
Total Stockholder Equity	0.93	0.5		-0.15	0.16	0.16	0.24	0.87	0.4	0.3	-0.89	0.93	0.58	0.95	0.24	0.1	0.82	0.52	0.53	0.38	0.91	0.79	-0.77	-0.83	-0.28	0.76
Net Debt	0.1	0.45	-0.15		-0.96	-0.96	0.26	0.31	0.47	-0.88	-0.25	0.13	0.46	0.13	-0.02	0.1	0.28	0.5	0.07	0.31	0.23	0.25	-0.31	-0.23	0.43	0.33
Cash	-0.03	-0.28	0.16	-0.96		1.0	-0.14	-0.27	-0.31	0.95	0.23	-0.13	-0.53	-0.13	0.17	0.11	-0.21	-0.37	-0.01	-0.3	-0.22	-0.15	0.16	0.12	-0.19	-0.18
Cash And Short Term Investments	-0.03	-0.28	0.16	-0.96	1.0		-0.14	-0.27	-0.31	0.95	0.23	-0.13	-0.53	-0.13	0.17	0.11	-0.21	-0.37	-0.01	-0.3	-0.22	-0.15	0.16	0.12	-0.19	-0.18
Net Receivables	0.48	0.67	0.24	0.26	-0.14	-0.14		0.36	0.75	0.12	-0.29	0.15	0.3	0.28	0.41	0.57	0.46	0.74	-0.14	0.7	0.27	0.52	-0.48	-0.33	0.26	0.52
Common Stock Shares Outstanding	0.95	0.72	0.87	0.31	-0.27	-0.27	0.36		0.66	-0.13	-0.98	0.96	0.82	0.95	0.2	0.14	0.92	0.77	0.4	0.46	0.99	0.88	-0.84	-0.85	-0.06	0.85
Total Liab	0.7	0.97	0.4	0.47	-0.31	-0.31	0.75	0.66		-0.12	-0.63	0.46	0.52	0.51	0.55	0.67	0.78	0.94	-0.01	0.56	0.56	0.83	-0.71	-0.61	0.45	0.76
Total Current Assets	0.15	-0.08	0.3	-0.88	0.95	0.95	0.12	-0.13	-0.12		0.11	-0.04	-0.44	0.01	0.32	0.28	-0.04	-0.17	0.06	0.01	-0.1	0.03	-0.03	-0.07	-0.14	0.01
Retained Earnings	-0.94	-0.7	-0.89	-0.25	0.23	0.23	-0.29	-0.98	-0.63	0.11		-0.96	-0.8	-0.96	-0.24	-0.14	-0.94	-0.72	-0.42	-0.44	-0.98	-0.9	0.82	0.85	0.12	-0.83
Other Stockholder Equity	0.92	0.55	0.93	0.13	-0.13	-0.13	0.15	0.96	0.46	-0.04	-0.96		0.75	0.97	0.12	-0.01	0.86	0.59	0.51	0.33	0.98	0.8	-0.77	-0.83	-0.21	0.77
Other Current Liab	0.68	0.48	0.58	0.46	-0.53	-0.53	0.3	0.82	0.52	-0.44	-0.8	0.75		0.74	-0.04	-0.1	0.71	0.61	-0.02	0.45	0.82	0.63	-0.45	-0.45	-0.34	0.48
Net Tangible Assets	0.94	0.59	0.95	0.13	-0.13	-0.13	0.28	0.95	0.51	0.01	-0.96	0.97	0.74		0.22	0.08	0.89	0.67	0.51	0.44	0.97	0.84	-0.81	-0.85	-0.23	0.81
Property Plant And Equipment Net	0.38	0.57	0.24	-0.02	0.17	0.17	0.41	0.2	0.55	0.32	-0.24	0.12	-0.04	0.22		0.94	0.4	0.55	0.1	0.29	0.14	0.51	-0.49	-0.44	0.38	0.51
Accounts Payable	0.31	0.66	0.1	0.1	0.11	0.11	0.57	0.14	0.67	0.28	-0.14	-0.01	-0.1	0.08	0.94		0.34	0.59	-0.02	0.35	0.04	0.47	-0.46	-0.38	0.59	0.49
Non Current Assets Total	0.92	0.84	0.82	0.28	-0.21	-0.21	0.46	0.92	0.78	-0.04	-0.94	0.86	0.71	0.89	0.4	0.34		0.82	0.38	0.53	0.89	0.99	-0.86	-0.85	0.04	0.88
Other Assets	0.78	0.92	0.52	0.5	-0.37	-0.37	0.74	0.77	0.94	-0.17	-0.72	0.59	0.61	0.67	0.55	0.59	0.82		0.13	0.56	0.68	0.86	-0.8	-0.7	0.31	0.84
Inventory	0.4	0.19	0.53	0.07	-0.01	-0.01	-0.14	0.4	-0.01	0.06	-0.42	0.51	-0.02	0.51	0.1	-0.02	0.38	0.13		0.05	0.44	0.36	-0.66	-0.7	0.19	0.6
Other Current Assets	0.51	0.59	0.38	0.31	-0.3	-0.3	0.7	0.46	0.56	0.01	-0.44	0.33	0.45	0.44	0.29	0.35	0.53	0.56	0.05		0.43	0.53	-0.46	-0.51	-0.03	0.48
Common Stock	0.94	0.63	0.91	0.23	-0.22	-0.22	0.27	0.99	0.56	-0.1	-0.98	0.98	0.82	0.97	0.14	0.04	0.89	0.68	0.44	0.43		0.84	-0.8	-0.83	-0.18	0.8
Property Plant Equipment	0.91	0.89	0.79	0.25	-0.15	-0.15	0.52	0.88	0.83	0.03	-0.9	0.8	0.63	0.84	0.51	0.47	0.99	0.86	0.36	0.53	0.84		-0.88	-0.86	0.13	0.9
Other Liab	-0.87	-0.82	-0.77	-0.31	0.16	0.16	-0.48	-0.84	-0.71	-0.03	0.82	-0.77	-0.45	-0.81	-0.49	-0.46	-0.86	-0.8	-0.66	-0.46	-0.8	-0.88		0.96	-0.34	-1.0
Non Current Liabilities Total	-0.88	-0.76	-0.83	-0.23	0.12	0.12	-0.33	-0.85	-0.61	-0.07	0.85	-0.83	-0.45	-0.85	-0.44	-0.38	-0.85	-0.7	-0.7	-0.51	-0.83	-0.86	0.96		-0.21	-0.95
Short Long Term Debt Total	-0.04	0.47	-0.28	0.43	-0.19	-0.19	0.26	-0.06	0.45	-0.14	0.12	-0.21	-0.34	-0.23	0.38	0.59	0.04	0.31	0.19	-0.03	-0.18	0.13	-0.34	-0.21		0.35
Current Deferred Revenue	0.89	0.85	0.76	0.33	-0.18	-0.18	0.52	0.85	0.76	0.01	-0.83	0.77	0.48	0.81	0.51	0.49	0.88	0.84	0.6	0.48	0.8	0.9	-1.0	-0.95	0.35

Click cells to compare fundamentals

Voyageur Pharmaceuticals Account Relationship Matchups

Voyageur Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.3M	2.6M	2.1M	2.2M	2.5M	2.6M
Total Current Liabilities	910.3K	621.1K	591.3K	673.9K	775.0K	418.5K
Total Stockholder Equity	306.3K	1.9M	1.5M	1.4M	1.7M	1.7M
Net Debt	265.4K	(770.9K)	(6.0K)	37.9K	43.6K	45.8K
Cash	3.0K	813.0K	31.6K	2.1K	1.9K	1.8K
Cash And Short Term Investments	3.0K	813.0K	31.6K	2.1K	1.9K	1.8K
Net Receivables	12.7K	41.5K	23.9K	35.9K	41.3K	35.5K
Common Stock Shares Outstanding	70.5M	94.7M	107.8M	130.5M	150.1M	157.6M
Liabilities And Stockholders Equity	1.3M	2.6M	2.1M	2.2M	2.5M	2.6M
Total Liab	968.8K	660.6K	630.8K	727.9K	837.1K	484.9K
Total Current Assets	25.5K	887.3K	157.2K	88.6K	101.9K	96.8K
Retained Earnings	(3.9M)	(6.0M)	(7.7M)	(9.1M)	(8.2M)	(7.8M)
Other Stockholder Equity	791.1K	1.6M	1.6M	1.9M	2.1M	2.2M
Other Current Liab	49.1K	24.0K	1.0	673.7K	774.7K	813.4K
Net Tangible Assets	515.7K	754.1K	306.3K	1.9M	2.2M	2.3M
Property Plant And Equipment Net	1.2M	1.7M	1.9M	5.8K	6.7K	6.4K
Accounts Payable	662.4K	584.7K	591.3K	218.01	250.71	238.18
Non Current Assets Total	1.2M	1.7M	1.9M	2.1M	2.4M	1.3M
Other Current Assets	12.67	23.1K	91.4K	76.2K	87.7K	61.2K
Common Stock	3.4M	6.3M	7.6M	8.7M	10.0M	10.5M
Property Plant Equipment	1.0M	1.2M	1.2M	1.7M	1.9M	974.4K
Non Current Liabilities Total	38.1K	58.5K	39.5K	54K	48.6K	46.2K
Short Long Term Debt Total	268.4K	42.1K	25.5K	40K	36K	34.2K
Net Invested Capital	545.3K	1.9M	1.5M	1.5M	1.7M	1.1M
Net Working Capital	(884.8K)	266.2K	(434.1K)	(585.2K)	(673.0K)	(706.7K)
Short Term Debt	8.6K	114.5K	223.9K	16.6K	19.0K	18.1K
Capital Stock	3.4M	6.3M	7.6M	8.7M	10.0M	5.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Voyageur Stock Analysis

When running Voyageur Pharmaceuticals' price analysis, check to measure Voyageur Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyageur Pharmaceuticals is operating at the current time. Most of Voyageur Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Voyageur Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyageur Pharmaceuticals' price. Additionally, you may evaluate how the addition of Voyageur Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Voyageur Historical Balance Sheet

Voyageur Pharmaceuticals Inventory

12,465.02

About Voyageur Balance Sheet Analysis

Voyageur Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Cash And Short Term Investments

Voyageur Pharmaceuticals balance sheet Correlations

Voyageur Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Voyageur Pharmaceuticals balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Voyageur Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Common Stock	+ 0.99	Common Stock Shares Outstanding
Property Plant Equipment	+ 0.99	Non Current Assets Total
Common Stock	+ 0.98	Other Stockholder Equity
Total Liab	+ 0.97	Total Current Liabilities
Net Tangible Assets	+ 0.97	Other Stockholder Equity

Current Deferred Revenue	- 1.0	Other Liab
Common Stock	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Common Stock Shares Outstanding
Net Tangible Assets	- 0.96	Retained Earnings
Other Stockholder Equity	- 0.96	Retained Earnings
Cash And Short Term Investments	- 0.96	Net Debt